Chart, Cash and Scenarios, page-42

Jev we learned at the AGM that the OxyC topical trials would be quick and cheap as POH does not wish to waste precious capital on trials that may not deliver. POH has referred to OxyC Topical as having a greater risk as it falls outside POHs normal strategy
From March 14 POH Newsletter:
" The oxycodone strategy falls outside our normal strategy. We know that we have an elegant patch that delivers oxycodone topically. However, we do not know whether it will be clinically efficacious when delivered in this manner. This is a departure from our strategy. However we have taken this approach because of the large market size of the peripheral pain market; because we are dealing with a disease state that is poorly treated with current clinical strategies and lastly because of the large commercial outcome that an opioid with little side effects and little potential of abuse would have in the market. When taking all these factors into account, the potential rewards outweigh the risks."

and further

"If the topical application of opioids succeeds, we will be establishing a new market for these class of products"


Harry Rosen has described why POHs main focus is now OxyM . He has stated in the same newsletter :
"The successful multiple dose trial announced in October 2013 indicates that the efficacy of the TPM®/Oxymorphone patch can reasonably be presumed. This confidence is based on the fact that each subject attained oxymorphone plasma levels in the therapeutic range (measured by reference to published plasma levels for the oral dosage form of Opana®) during the first rotation of the patch.
...our focus remains squarely on oxymorphone because of its potential market size and because we have established that we can deliver it into the plasma in therapeutic concentrations"